Feline Inflammatory Polyps: Imaging and Treatment Selection

Bottom line

Feline inflammatory polyp treatment should follow localization and assessment of middle-ear involvement, not simply removal of the visible portion. Examination should include both ear canals and the nasopharynx; histopathology establishes the diagnosis. [1] Select a removal approach around lesion extent, access, concurrent ear disease, available expertise and the client's ability to pursue follow-up. Do not present recurrence estimates from unlike retrospective cohorts as a causal comparison of procedures.

Localize aural, nasopharyngeal and competing disease

Aural inflammatory polyps originate from the tympanic bulla or auditory tube and may produce otitis externa, media or interna signs. [2] Record otorrhea, canal patency, pain and neurologic findings before intervention. Do not let an accessible canal mass substitute for assessing disease extent.

Stertor, nasal discharge, sneezing, dysphagia or dyspnea may accompany nasopharyngeal extension. [1] Respiratory compromise takes priority over an elective diagnostic sequence. Establish a handling and airway plan before prolonged oral manipulation in an unstable cat. The feline dysphonia workup covers laryngeal localization when voice change or stridor is prominent rather than assuming every upper-airway sign is a polyp.

Keep the presenting lesion anatomically precise. A swollen pinna requires its own hematoma and underlying otitis assessment. Nasal bleeding that is disproportionate to the visible lesion calls for a broader local versus systemic epistaxis workup. These pathways complement, rather than replace, direct lesion assessment.

Image both sides when defining the treatment field

Advanced imaging can reveal contralateral disease not apparent from the presenting complaint. Hoppers and colleagues' retrospective series documented bilateral inflammatory polyps and identified contralateral lesions using advanced imaging at referral. [3] This supports assessing both sides; it does not establish a universal prevalence for every practice population.

CT or MRI can characterize suspected bulla disease that is inaccessible to otoscopy. [1] Before choosing a procedure, ask whether imaging will change the surgical field, referral decision or consent discussion. Record which compartments and adjacent structures can actually be assessed, and distinguish an imaging suspicion from a histologic diagnosis.

Plan tissue submission at removal. Retain an explicit differential diagnosis for an atypical, invasive or unusually located mass rather than allowing a smooth appearance to settle the diagnosis.

Choose removal around bulla involvement and access

Traction-avulsion can be a reasonable initial approach in selected cats, but underlying middle-ear findings matter. In Veir and colleagues' retrospective series, recurrent polyps after initial traction-avulsion occurred in cats with radiographic bulla disease; the authors supported traction in cats without evidence of bulla involvement. [4] This is selection-relevant observational evidence, not proof that normal imaging guarantees durable resolution.

Discuss bulla surgery when disease or access makes a limited approach unsuitable, or after recurrence. Souza and Simpson describe bulla osteotomy as an option in complicated cases and emphasize addressing secondary infection. [2] Match the procedure to the lesion and operator's capabilities rather than assigning every cat the same first-line intervention.

Per-endoscopic trans-tympanic traction is another reported option for aural disease. Greci and colleagues described this technique in a retrospective case review, including recurrent polyps and postoperative Horner syndrome. [5] It is an expertise-dependent option, not a demonstration that endoscopy is superior to surgery across all disease presentations.

Separate adjunctive treatment from definitive lesion control

Antimicrobial decisions should address secondary infection rather than label every polyp bacterial. The professional reference recommends culture of bulla material to guide systemic antimicrobial treatment. [1] Document sampling location and prior treatment so the result can be interpreted in context.

The evidence for glucocorticoid-associated reduction in recurrence is not uniform. A review describes adjunctive systemic glucocorticoids favorably. [2] However, the bilateral-polyp retrospective study did not identify differences in recurrence with versus without local and systemic steroid administration between its groups. [3] Neither source justifies promising that steroids prevent regrowth. Make an individualized risk-benefit decision; this hub does not supply an empirical dosing protocol.

Consent and reassess the whole clinical problem

Consent should distinguish possible persistence of middle-ear disease from regrowth of a removed lesion. Explain the chosen access route, what remains uncertain and what would prompt re-imaging or a different procedure. Neurologic complications, including Horner syndrome and facial nerve paralysis, are reported after polyp treatment. [5] Record baseline findings so postoperative changes can be recognized.

Recheck comfort, ear discharge, canal access, respiratory or swallowing signs and neurologic status. Persistent signs should reopen localization rather than automatically trigger another empirical drug course. Provide a specific return plan for worsening breathing, swallowing difficulty or new neurologic deficits, and document who will manage recurrence if referral was involved.

Frequently Asked Questions

Must both ears be assessed with a unilateral presentation?

Yes. Contralateral disease may be identified by advanced imaging even when the initial presentation seems unilateral. [3] Record findings on both sides before deciding the extent of treatment.

Does a visible canal mass define the full lesion?

No. Consider the middle ear and nasopharynx rather than treating the accessible portion as the entire disease process. Plan imaging and tissue submission according to what remains uncertain.

When is traction-avulsion reasonable?

It is an option in selected, accessible lesions. Bulla involvement, recurrence, access and available expertise should influence the choice. Do not promise that a limited procedure will be definitive.

When should bulla osteotomy be considered?

Consider it in complicated or recurrent disease and when adequate lesion access cannot be achieved with the proposed less invasive approach. Discuss the rationale and procedural risks with the client rather than framing surgery as automatically necessary for every polyp.

Do glucocorticoids guarantee that a polyp will not recur?

No. Published reports differ, and retrospective treatment selection complicates interpretation. Explain the uncertainty and make an individualized decision rather than using adjunctive medication as a substitute for reassessment.

Can recurrence percentages be compared directly between studies?

Not as a causal ranking. Populations, disease extent, techniques, operators and follow-up differ. Use the studies to inform consent and selection, while keeping those limitations explicit.